磁共振成像与经直肠超声评估前列腺体积及前列腺特异性抗原密度的比较:对前列腺癌检出的影响
该研究比较了多参数磁共振成像(mpMRI)与经直肠超声(TRUS)评估前列腺体积和前列腺特异性抗原密度(PSAD)的差异,并分析其对前列腺癌检出的影响。结果显示TRUS低估前列腺体积,基于mpMRI的PSAD与前列腺癌检出关联略优于TRUS,但PSAD在较大前列腺中效用可能有限。
要点
- TRUS较mpMRI低估前列腺体积(中位数49.2cc vs 54.1cc)。
- mpMRI PSAD检出任何前列腺癌的OR为2.94,TRUS PSAD为2.78,均P<.001。
- 前列腺体积≥77.5cc时,PSAD与前列腺癌检出无关联。
核心结论
- TRUS相对于mpMRI低估前列腺体积。
- 基于mpMRI的PSAD可能较TRUS与前列腺癌检出关联更好,但PSAD在较大前列腺中效用可能有限。
研究设计与样本
- 研究纳入2015年至2020年间在mpMRI-TRUS融合引导前列腺穿刺活检前接受mpMRI的患者640例。
- 比较mpMRI与TRUS测量的前列腺体积及计算的PSAD。
- 采用线性回归(按体积四分位交互)、逻辑回归和受试者工作特征曲线评估与任何前列腺癌及临床显著前列腺癌(csPCa;Gleason≥3+4)的关联。
主要发现
- TRUS较mpMRI低估前列腺体积(中位数49.2cc vs 54.1cc),体积≤77.5cc(第一至第三四分位)时每cc低8%,体积>77.5cc(第四四分位)时每额外cc低39%。
- 在接受根治性前列腺切除术的男性中,与手术病理相比,mpMRI的相关系数高于TRUS(0.913 vs 0.878)。
- mpMRI PSAD检出任何前列腺癌的OR为2.94,TRUS PSAD为2.78,均P<.001;检出csPCa的OR分别为4.20和4.02,均P<.001。
- mpMRI与TRUS PSAD的AUC改善对于任何前列腺癌为临界显著性(0.689 vs 0.675,P=.05),对于csPCa不显著(0.732 vs 0.722,P=.20)。
- 前列腺体积≥77.5cc时,PSAD与前列腺癌检出无关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare multiparametric magnetic resonance imaging (mpMRI) and transrectal ultrasound (TRUS) to estimate prostate volume and prostate specific antigen density (PSAD) as well as subsequent impact on prostate cancer (PCa) detection. METHODS: Patients referred for mpMRI prior to mpMRI-TRUS fusion-guided prostate biopsy between 2015 and 2020 were identified. Volume and calculated PSAD by mpMRI and TRUS were compared. Associations with presence of any PCa and clinically significant PCa (csPCa; Gleason ≥3 + 4) were evaluated using linear regression (interaction by volume quartile), logistic regression, and receiver operating characteristics. RESULTS: Among 640 men, TRUS underestimated prostate volume relative to mpMRI (median 49.2cc vs. 54.1cc) with 8% lower volume per cc up to 77.5cc (First-third quartile) and 39% lower volume per additional cc above 77.5cc (fourth quartile). For men undergoing radical prostatectomy, mpMRI had a higher correlation coefficient relative to TRUS (0.913 vs 0.878) when compared to surgical pathology. mpMRI PSAD had slightly higher odds vs TRUS PSAD for detecting any PCa (OR 2.94 and OR 2.78, both P <.001) or csPCa (OR 4.20 and OR 4.02, both P <.001). AUC improvements were of borderline significance for mpMRI vs. TRUS PSAD for any PCa (0.689 vs 0.675, P = .05) and not significant for csPCa (0.732 vs 0.722, P = .20). PSAD was not associated with PCa detection for prostates ≥77.5cc. CONCLUSION: TRUS underestimates prostate volume relative to mpMRI. PSAD based on mpMRI may be better associated with detection of PCa compared to TRUS, but utility of PSAD may be limited for larger prostates.
引用
- Choe S, Patel HD, Lanzotti N, et al. MRI vs Transrectal Ultrasound to Estimate Prostate Volume and PSAD: Impact on Prostate Cancer Detection. Urology. 2022. PMID: 36152871. doi:10.1016/j.urology.2022.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。